In an acute ischemic stroke patient, should clevidipine and nicardipine (Cardene) infusions be started, or is permissive hypertension preferred?

Blood Pressure Management in Acute Ischemic Stroke: When to Use IV Antihypertensives

You are correct that permissive hypertension is the standard approach for most acute ischemic stroke patients, but clevidipine and nicardipine (Cardene) drips are absolutely indicated in specific situations—primarily when patients are candidates for thrombolytic therapy or have extreme hypertension.

The Clinical Algorithm

1. For Patients Receiving or Eligible for tPA/Alteplase

Blood pressure MUST be lowered if >185/110 mmHg before giving tPA, and maintained <180/105 mmHg for 24 hours after treatment 1, 2, 3. This is a Class I recommendation based on the inclusion criteria from pivotal thrombolysis trials. High BP during the first 24 hours after tPA significantly increases the risk of symptomatic intracranial hemorrhage 2.

Recommended agents for this scenario:

• Nicardipine: Start at 5 mg/hr IV, titrate by 2.5 mg/hr every 5-15 minutes, maximum 15 mg/hr 1, 3
• Clevidipine: Start at 1-2 mg/hr IV, double the dose every 2-5 minutes until desired BP reached, maximum 21 mg/hr 3, 4
• Labetalol: 10-20 mg IV over 1-2 minutes, may repeat once 1

Both clevidipine and nicardipine are explicitly listed in AHA/ASA guidelines as appropriate first-line options 3. Clevidipine has demonstrated faster time to target BP in stroke populations, with median time to goal of 15 minutes in a large institutional study 5.

2. For Patients NOT Receiving Thrombolysis

This is where permissive hypertension applies, but with important thresholds:

BP <220/120 mmHg:

• Do NOT treat acutely (Class III: No Benefit) 2, 6. Initiating or reinitiating antihypertensive therapy within the first 48-72 hours is not effective to prevent death or dependency and may be harmful 2.
• The brain requires elevated perfusion pressure due to impaired cerebral autoregulation in the ischemic penumbra 7, 6.

BP ≥220/120 mmHg:

• Consider cautious lowering by approximately 15% over the first 24 hours (Class IIb) 2, 8, 6
• Use titratable IV agents (nicardipine, clevidipine, or labetalol) to avoid precipitous drops 1
• Avoid lowering more than 25% in the first 24 hours 8

3. After the Acute Phase (>24 hours)

For neurologically stable patients with BP >140/90 mmHg, restarting antihypertensive therapy is reasonable to improve long-term BP control (Class IIa) 2, 7.

Why Permissive Hypertension Exists

The rationale is physiologic: cerebral autoregulation is disrupted in acute stroke, making the ischemic penumbra dependent on systemic perfusion pressure for blood flow and oxygen delivery 6. Multiple trials have shown that aggressive BP lowering in the acute phase (without thrombolysis) does not improve outcomes and may worsen them:

• The CATIS trial (n=2004) showed that BP reduction with candesartan actually resulted in worse functional outcomes at 6 months 1
• A study using nicardipine in acute stroke showed that excessive BP drops (>20% from baseline) were associated with decreased cerebral blood flow and worse outcomes 9
• Studies consistently demonstrate a U-shaped relationship between admission BP and outcomes, with optimal ranges around 121-200 mmHg systolic 7, 6

Common Pitfalls to Avoid

1. Don't treat BP <220/120 mmHg in non-thrombolysis candidates unless there are other compelling indications (acute MI, aortic dissection, pulmonary edema) 2, 8

2. Avoid rapid or excessive BP drops - even lowering to "normal" hypertensive ranges can be detrimental in acute stroke 8, 6. Target controlled reductions, not normalization.

3. Don't use short-acting nifedipine - it causes unpredictable, precipitous BP drops 8, 10

4. Monitor frequently - BP should be checked every 15 minutes for 2 hours after starting tPA, then every 30 minutes for 6 hours, then hourly for 16 hours 1, 3

Practical Considerations

Clevidipine vs. Nicardipine: Both are equally effective and safe for acute stroke 11, 12. Clevidipine may achieve target BP slightly faster (median 15 vs. 39 minutes in some studies) 5 and requires lower infusion volumes 11, but nicardipine is significantly less expensive ($2.20 vs. $71.40) 12. Either is appropriate; institutional availability and cost often drive the choice.

Labetalol as an alternative: Intermittent labetalol boluses achieve similar door-to-needle times as continuous infusions and are much less expensive 12, 13, making them a reasonable first-line option if BP is only moderately elevated.